Trisalus Life Sciences Inc (TLSI) Stock Price, Quote & News

Company Profile

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; an...

Industry: Medical Devices

Sector: Healthcare

Phone: 888 321 5212

Website: trisaluslifesci.com

Address:

6272 West 91st Avenue, Westminster, United States

EarningsInsider Aug. 6 at 9:22 PM

https://www.marketbeat.com/earnings/reports/2026-8-6-trisalus-life-sciences-inc-stock/ $TLSI TriSalus Life Sciences Earnings Transcript

0 · Reply

StocktwitsEarnings Aug. 6 at 8:10 PM

$TLSI Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.16 up 40.74% YoY • Reported revenue of $11.41M up 1.73% YoY

0 · Reply

AccuRoger Jul. 25 at 12:35 AM

$TLSI This multi year study is now complete. Results should be presented soon. https://clinicaltrials.gov/study/NCT05128032

0 · Reply

AccuRoger Jul. 23 at 7:20 PM

$TLSI The PEDD Liver Tumor Trial is proceeding. The protection of normal liver tissue is important. This study will validate the value of pressure enabled dosing over standard end-hole catheters. https://www.mpo-mag.com/breaking-news/trisalus-life-sciences-initiates-predictt-clinical-trial/

0 · Reply

AccuRoger Jul. 23 at 1:05 PM

$TLSI New detailed article. Quote Clinical data, while predominantly retrospective, indicate that PEDD is safe in patients with complex profiles and improve pathologic tumor response during DEM-TACE. Real-world evidence confirms comparable or improved safety alongside reductions in post-procedure complications and healthcare utilization [79,80]. The application of PEDD to regional immunotherapy, including CAR-T cells and TLR9 agonists, capitalizes on the distinct immunobiology of the hepatic microenvironment https://www.mdpi.com/2072-6694/18/15/2367

0 · Reply

irdoc11 Jul. 13 at 6:04 PM

$TLSI big news. TriSalus granted HCPCS Code G0577 by CMS. HCPCS Code G0577 for Vascular embolization or occlusion procedure with use of a pressure-generating catheter (e.g., one-way valve, intermittently occluding), inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; for tumors, organ ischemia, or infarction performed in the non-facility setting This would increase annual TriNav catheter usage by multiple factors as more uterine artery embolization cases are currently being done in the OBL (non-facility) setting. https://www.aapc.com/codes/hcpcs-codes/G0577?srsltid=AfmBOor6aAisDMhrGCP_uFi6kPTXiVmi0uBgXxPKcMy35ocKklM_XrmL

0 · Reply

AccuRoger Jun. 19 at 3:12 PM

$TLSI Here is an update podcast on using the TriNav PEDD for fibroids. Listen to the 30 minute mark to the end. Exceptional results are described. They also discuss preliminary research results and plans for growth of the practice. https://www.backtable.com/shows/vi/podcasts/656/advanced-practices-in-uterine-fibroid-embolization

0 · Reply

Pastures Jun. 6 at 5:20 PM

$TLSI What price target are you hoping for?

1 · Reply

Tdavis_19 May. 24 at 4:16 PM

$TLSI any news we’re looking for any time soon? Pt?

1 · Reply

PLATINUM_TRADES May. 19 at 2:06 PM

$TLSI Still going 🚨🚨

0 · Reply

TriSalus Life Sciences reports Q2 EPS (16c), consensus (16c)

2026-08-06T20:31:26.000Z - 21 hours ago

TriSalus Life Sciences sees FY26 revenue $54M-$57M, consensus $52.4M

Aug 6, 2026, 4:30 PM EDT - 21 hours ago

TriSalus Life Sciences Earnings Call Transcript: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 21 hours ago

TriSalus Life Sciences Earnings release: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 21 hours ago

TriSalus Life Sciences Quarterly report: Q2 2026

Aug 6, 2026, 4:05 PM EDT - 22 hours ago

TriSalus Life Sciences Reports Second Quarter 2026 Results

Jul 29, 2026, 4:05 PM EDT - 8 days ago

TriSalus Life Sciences to Participate in the Canaccord Genuity 46th Annual Growth Conference

Jul 16, 2026, 4:05 PM EDT - 21 days ago

TriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference Call

2026-06-10T12:15:42.000Z - 2 months ago

TriSalus Life Sciences to host KOL event featuring RWE on PEDD

Jun 10, 2026, 8:00 AM EDT - 2 months ago

TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer

2026-05-13T15:22:58.000Z - 3 months ago

TriSalus Life Sciences price target lowered to $8 from $10 at Lake Street

2026-05-12T22:14:02.000Z - 3 months ago

TriSalus Life Sciences reports Q EPS 3c, one estimate (16c)

May 12, 2026, 4:30 PM EDT - 3 months ago

TriSalus Life Sciences Earnings Call Transcript: Q1 2026

May 12, 2026, 4:30 PM EDT - 3 months ago

TriSalus Life Sciences Earnings release: Q1 2026

May 12, 2026, 4:30 PM EDT - 3 months ago

TriSalus Life Sciences Quarterly report: Q1 2026

May 12, 2026, 4:01 PM EDT - 3 months ago

TriSalus Life Sciences Reports First Quarter 2026 Results Demonstrating Commercial and Clinical Progress for Facilitating Long-Term Growth

2026-05-12T16:00:15.000Z - 3 months ago

TriSalus announces journal publication of PEDD study

May 12, 2026, 8:00 AM EDT - 3 months ago

Real-World PEDD Study Published in the Journal of Comparative Effectiveness Research Shows Improved Clinical Outcomes and Meaningful Charge Avoidance

May 4, 2026, 5:24 PM EDT - 3 months ago

TriSalus Life Sciences Announces Launch of PREDICTT Clinical Trial Evaluating Pressure-Enabled Drug Delivery in Liver Tumors

Apr 28, 2026, 4:05 PM EDT - 3 months ago

TriSalus Life Sciences to Host First Quarter 2026 Financial Results Conference Call

Apr 15, 2026, 7:00 AM EDT - 4 months ago

TriSalus Life Sciences Slides: Investor presentation

Apr 9, 2026, 4:05 PM EDT - 4 months ago

TriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific Meeting

2026-04-07T13:41:02.000Z - 4 months ago

TriSalus Life Sciences appoints Marshall as Chief Medical Officer

Apr 7, 2026, 9:15 AM EDT - 4 months ago

TriSalus Life Sciences Appoints Richard Marshall, M.D., as Chief Medical Officer

Mar 31, 2026, 8:00 AM EDT - 4 months ago

TriSalus Life Sciences Proxy statement: Proxy filing

Mar 31, 2026, 8:00 AM EDT - 4 months ago

TriSalus Life Sciences Proxy statement: Proxy filing

2026-03-23T13:17:40.000Z - 4 months ago

TriSalus Life Sciences price target lowered to $8 from $12.50 at Northland

Mar 18, 2026, 8:00 AM EDT - 5 months ago

TriSalus Life Sciences Announces Publication Demonstrating Enhanced Delivery and Immune Activation with Nelitolimod Delivered with Pressure-Enabled Drug Delivery in Liver Tumor Models

2026-03-06T11:55:11.000Z - 5 months ago

TriSalus Life Sciences price target lowered to $7 from $12 at Canaccord

Mar 5, 2026, 4:30 PM EST - 5 months ago

TriSalus Life Sciences Earnings Call Transcript: Q4 2025

Mar 5, 2026, 4:30 PM EST - 5 months ago

TriSalus Life Sciences Annual report: Q4 2025

Mar 5, 2026, 4:30 PM EST - 5 months ago

TriSalus Life Sciences Earnings release: Q4 2025

2026-03-05T21:11:39.000Z - 5 months ago

TriSalus Life Sciences sees FY26 revenue $60M-$62M, consensus $60.34M

2026-03-05T21:05:24.000Z - 5 months ago

TriSalus Life Sciences reports Q4 EPS (21c), consensus (14c)

Mar 5, 2026, 4:01 PM EST - 5 months ago

TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue Guidance

Feb 25, 2026, 4:05 PM EST - 5 months ago

TriSalus Life Sciences to Host Fourth Quarter 2025 Financial Results Conference Call

2026-02-20T14:23:30.000Z - 6 months ago

TriSalus Life Sciences 9.76M share Spot Secondary priced at $4.10

Feb 20, 2026, 8:00 AM EST - 6 months ago

TriSalus Life Sciences Announces Pricing of $40.0 Million Public Offering

2026-02-19T21:06:06.000Z - 6 months ago

TriSalus Life Sciences announces common stock offering, no amount given

Feb 19, 2026, 4:01 PM EST - 6 months ago

TriSalus Life Sciences Proposes Public Offering

2026-02-09T14:10:56.000Z - 6 months ago

TriSalus Life Sciences appoints Stansky to board of directors

Feb 9, 2026, 9:00 AM EST - 6 months ago

TriSalus Life Sciences Appoints Veteran Healthcare Investor Michael Stansky to its Board of Directors

2026-01-12T12:12:59.000Z - 7 months ago

TriSalus Life Sciences sees FY26 revenue $60M-$62M, consensus $63.77M

2026-01-12T12:05:59.000Z - 7 months ago

TriSalus Life Sciences reports preliminary Q4 revenue $13.2M, consensus $12.68M

Jan 12, 2026, 7:00 AM EST - 7 months ago

TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance

2026-01-08T14:35:32.000Z - 7 months ago

TriSalus Life Sciences named a 2026 Top Pick at Northland

2025-12-17T12:25:53.000Z - 8 months ago

TriSalus Life Sciences price target raised to $12 from $11 at Canaccord

Dec 15, 2025, 2:00 PM EST - 8 months ago

TriSalus Life Sciences Transcript: KOL Event

Dec 11, 2025, 4:00 PM EST - 8 months ago

TriSalus Life Sciences Slides: Investor Presentation

Dec 4, 2025, 4:01 PM EST - 8 months ago

TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025

Dec 2, 2025, 3:10 PM EST - 8 months ago

TriSalus Life Sciences Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 20, 2025, 2:30 PM EST - 9 months ago

TriSalus Life Sciences Transcript: CG MedTech, Diagnostics and Digital Health & Services Forum

Nov 18, 2025, 8:00 AM EST - 9 months ago

TriSalus Life Sciences Launches TriNav® XP Infusion System to Expand Options for Pressure-Enabled Drug Delivery™

2025-11-13T21:46:39.000Z - 9 months ago

TriSalus Life Sciences files $150M mixed securities shelf

Nov 13, 2025, 4:30 PM EST - 9 months ago

TriSalus Life Sciences Earnings Call Transcript: Q3 2025

Nov 13, 2025, 4:30 PM EST - 9 months ago

TriSalus Life Sciences Quarterly report: Q3 2025

Nov 13, 2025, 4:30 PM EST - 9 months ago

TriSalus Life Sciences Earnings release: Q3 2025

2025-11-13T21:05:42.000Z - 9 months ago

TriSalus Life Sciences reports Q3 EPS (96c) vs (12c) last year

Nov 13, 2025, 4:01 PM EST - 9 months ago

TriSalus Life Sciences Reports Third Quarter 2025 Results and Reaffirms 2025 Revenue Guidance

Nov 13, 2025, 7:00 AM EST - 9 months ago

TriSalus Life Sciences Registration statement: Registration Filing

Nov 12, 2025, 10:00 AM EST - 9 months ago

TriSalus Life Sciences Transcript: KOL Event

Nov 11, 2025, 4:05 PM EST - 9 months ago

TriSalus Life Sciences to Participate in Upcoming Investor Conferences

Nov 10, 2025, 8:00 AM EST - 9 months ago

TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Uterine Fibroids on November 12, 2025

Oct 30, 2025, 8:00 AM EDT - 10 months ago

TriSalus Life Sciences to Host Third Quarter 2025 Financial Results Conference Call

Sep 5, 2025, 9:35 AM EDT - 1 year ago

TriSalus Life Sciences Transcript: Cantor Global Healthcare Conference 2025

Aug 28, 2025, 8:00 AM EDT - 1 year ago

TriSalus Life Sciences to Participate in Upcoming September Investor Conferences

Aug 12, 2025, 4:30 PM EDT - 1 year ago

TriSalus Life Sciences Earnings Call Transcript: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 1 year ago

TriSalus Life Sciences Quarterly report: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 1 year ago

TriSalus Life Sciences Earnings release: Q2 2025

Aug 12, 2025, 4:01 PM EDT - 1 year ago

TriSalus Life Sciences Reports Second Quarter 2025 Results and Reiterates 2025 Guidance

Aug 11, 2025, 8:00 AM EDT - 1 year ago

TriSalus Life Sciences Announces Publication of Safety and Efficacy Results for a Novel Pressure-Enabled Thyroid Embolization Technique

Jul 30, 2025, 4:05 PM EDT - 1 year ago

TriSalus Life Sciences to Participate in the Canaccord Genuity 45th Annual Growth Conference

Jul 29, 2025, 4:05 PM EDT - 1 year ago

TriSalus Life Sciences to Host Second Quarter 2025 Financial Results Conference Call

Jul 24, 2025, 5:58 PM EDT - 1 year ago

TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock

Jun 23, 2025, 5:30 PM EDT - 1 year ago

TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure

Jun 4, 2025, 8:00 AM EDT - 1 year ago

TriSalus Life Sciences Announces the Launch of the TriNav FLX Infusion System

May 30, 2025, 8:00 AM EDT - 1 year ago

TriSalus Life Sciences Registration statement: Registration Filing

May 30, 2025, 7:00 AM EDT - 1 year ago

TriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. Patience

May 15, 2025, 8:00 AM EDT - 1 year ago

TriSalus Life Sciences Earnings Call Transcript: Q1 2025

May 15, 2025, 8:00 AM EDT - 1 year ago

TriSalus Life Sciences Quarterly report: Q1 2025

May 15, 2025, 8:00 AM EDT - 1 year ago

TriSalus Life Sciences Earnings release: Q1 2025

May 15, 2025, 7:00 AM EDT - 1 year ago

TriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 Guidance

May 12, 2025, 4:30 PM EDT - 1 year ago

TriSalus Life Sciences to Host First Quarter 2025 Financial Results Conference Call

Apr 30, 2025, 8:00 AM EDT - 1 year ago

TriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial Results

Apr 30, 2025, 8:00 AM EDT - 1 year ago

TriSalus Life Sciences Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

TriSalus Life Sciences Registration statement: Registration Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

TriSalus Life Sciences Registration statement: Registration Filing

Mar 27, 2025, 8:00 AM EDT - 1 year ago

TriSalus Life Sciences Earnings Call Transcript: Q4 2024

Mar 27, 2025, 8:00 AM EDT - 1 year ago

TriSalus Life Sciences Annual report: Q4 2024

Mar 27, 2025, 8:00 AM EDT - 1 year ago

TriSalus Life Sciences Earnings release: Q4 2024

Mar 27, 2025, 7:30 AM EDT - 1 year ago

TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update

Mar 26, 2025, 8:00 AM EDT - 1 year ago

TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav® Infusion System Mapping

Mar 6, 2025, 8:00 AM EST - 1 year ago

TriSalus Life Sciences® Announces That Its Researchers Received Two JVIR Top Paper Awards for the Publication of “Intra-arterial Pressure-Enabled Drug Delivery™ Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model”

Feb 3, 2025, 4:05 PM EST - 1 year ago

TriSalus Life Sciences Announces Key Appointments to Board of Directors

Feb 3, 2025, 8:00 AM EST - 1 year ago

TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed

Jan 23, 2025, 8:00 AM EST - 1 year ago

TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference Call

Jan 9, 2025, 8:00 AM EST - 1 year ago

TriSalus Life Sciences® Announces Publication of Pre-Clinical Data Demonstrating Improved Delivery of Embospheres® to Liver Tumors using Pressure-Enabled Drug Delivery™ (PEDD™) via the TriNav® Infusion System

EarningsInsider Aug. 6 at 9:22 PM

https://www.marketbeat.com/earnings/reports/2026-8-6-trisalus-life-sciences-inc-stock/ $TLSI TriSalus Life Sciences Earnings Transcript

0 · Reply

StocktwitsEarnings Aug. 6 at 8:10 PM

$TLSI Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.16 up 40.74% YoY • Reported revenue of $11.41M up 1.73% YoY

0 · Reply

AccuRoger Jul. 25 at 12:35 AM

$TLSI This multi year study is now complete. Results should be presented soon. https://clinicaltrials.gov/study/NCT05128032

0 · Reply

AccuRoger Jul. 23 at 7:20 PM

0 · Reply

AccuRoger Jul. 23 at 1:05 PM

0 · Reply

irdoc11 Jul. 13 at 6:04 PM

0 · Reply

AccuRoger Jun. 19 at 3:12 PM

0 · Reply

Pastures Jun. 6 at 5:20 PM

$TLSI What price target are you hoping for?

1 · Reply

Tdavis_19 May. 24 at 4:16 PM

$TLSI any news we’re looking for any time soon? Pt?

1 · Reply

PLATINUM_TRADES May. 19 at 2:06 PM

$TLSI Still going 🚨🚨

0 · Reply

topstockalerts May. 19 at 12:25 AM

$TLSI there’s a certain stubbornness to this strength.

0 · Reply

CEOBuysDisclosures May. 18 at 10:45 PM

$TLSI CEO purchased 39,682 shares at $2.59 for a total of $102,776. Szela Mary T now owns 1,065,215 shares. https://ceo-buys.com

0 · Reply

PLATINUM_TRADES May. 18 at 9:04 PM

$TLSI $3.14 😜😜

0 · Reply

PLATINUM_TRADES May. 18 at 3:13 PM

$TLSI $2.99 High Close enough 2/2 day on overnights swings and 1 loss in the last 67 overnights 🥇🥇🥇🥇

0 · Reply

PLATINUM_TRADES May. 18 at 1:41 PM

$TLSI Overnight swing winner $2.87 to break for a shot at $3.00🚨🚨

0 · Reply

rapidtrades May. 15 at 3:17 PM

$TLSI 3

0 · Reply

rapidtrades May. 15 at 3:16 PM

$TLSI it's gonna make a move

0 · Reply

Axielg May. 14 at 10:55 PM

$TLSI this 44% drop seems abit excessive based solely on the missed quarterly revenue estimates. This is set for a correction.

0 · Reply

focafoca99 May. 14 at 8:14 PM

$TLSI held its annual meeting, electing two directors, ratifying Grant Thornton as auditor and approving an advisory vote on executive

0 · Reply

willem May. 14 at 5:53 PM

$TLSI stock raid for pennies.

0 · Reply

willem May. 14 at 5:44 PM

$TLSI What happened at 12:46???

0 · Reply

rapidtrades May. 14 at 4:32 PM

$TLSI buying more before the power hour

0 · Reply

Market Cap	283.75M
Revenue (ttm)	45.15M
Net Income (ttm)	-39.23M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-86.89%
Debt to Equity Ratio	2.58

Volume	567,747
Avg Vol	342,836
Day's Range	N/A - N/A
Shares Out	61.42M
Stochastic %K	93%
Beta	0.43
Analysts	Strong Sell
Price Target	$9.00